• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by Chiasma, Inc.

    8/6/21 3:12:11 PM ET
    $CHMA
    Major Pharmaceuticals
    Health Care
    Get the next $CHMA alert in real time by email
    POS AM 1 brhc10027584_posam.htm POS AM
    As filed with the Securities and Exchange Commission on August 6, 2021
    Registration No. 333-233654

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C.  20549


    POST-EFFECTIVE AMENDMENT NO. 1 TO

    FORM S-3
    REGISTRATION STATEMENT (REG. NO. 333-233654)

    UNDER THE SECURITIES ACT OF 1933


    CHIASMA, INC.
    (Exact name of registrant as specified in its charter)

    Delaware
     
    76-0722250
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification Number)

    140 Kendrick Street, Building C East
    Needham, Massachusetts 02494
    (Address, including zip code, of registrant’s principal executive offices)

    Rory Nealon
    c/o Chiasma, Inc.
    140 Kendrick Street, Building C East
    Needham, Massachusetts 02494
    (Name and address of agent for service)
    (617)-928-5300
    (Telephone number, including area code, of agent for service)
     


    Approximate date of commencement of proposed sale to the public: Not applicable
     
    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box:  ☐
     
    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box:  ☐
     
    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering:  ☐
     
    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ☐
     
    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ☐
     
    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ☐
     
    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
     
    Large accelerated filer
    ☐
    Accelerated filer
    ☐
           
    Non-accelerated filer
    ☒
    Smaller reporting company
    ☒
           
    Emerging growth company
    ☐
       

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    DEREGISTRATION OF SECURITIES

    This Post-Effective Amendment No. 1 (this “Post-Effective Amendment”) relates to the Registration Statement on Form S-3 (File No. 333-233654), initially filed with the Securities and Exchange Commission on September 6, 2019 (as amended, the “Registration Statement”) by Chiasma, Inc., a Delaware corporation (the “Registrant”), pertaining to the registration of up to $200,000,000 of an indeterminate amount of common stock, preferred stock, debt securities, warrants and/or units.
     
    On August 5, 2021, pursuant to the terms of an Agreement and Plan of Merger (the “Merger Agreement”) dated as of May 4, 2021 by and among Amryt Pharma plc, a public limited company incorporated under the laws of England and Wales (“Amryt”), Acorn Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Amryt (“Merger Sub”), and the Registrant, Merger Sub merged with and into the Registrant, with the Registrant surviving the merger as an indirect, wholly owned subsidiary of Amryt (the “Merger”).
     
    As a result of the Merger, the Registrant has terminated any and all offerings of its securities pursuant to the Registration Statement. In accordance with an undertaking made by the Registrant in the Registration Statement to remove from registration, by means of a post-effective amendment, any of the securities registered under the Registration Statement that remain unissued at the termination of the offering, the Registrant hereby removes from registration all securities registered but unsold under such Registration Statement, if any, as of the date hereof.


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this Post-Effective Amendment to be signed on its behalf by the undersigned, thereunto duly authorized, in Dublin, Ireland on August 6, 2021.

     
    Chiasma, Inc.
         
      By: /s/ Rory Nealon
     
    Name:
    Rory Nealon
     
    Title:
    Authorized Signatory
     
    No other person is required to sign this Post-Effective Amendment in reliance upon Rule 478 under the Securities Act of 1933.



    Get the next $CHMA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CHMA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $CHMA
    Financials

    Live finance-specific insights

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q1 2022 Results

      Amryt Reports Record Q1 2022 Results CHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Board approved stock repurchase program of up to $30M Cash of $102.2M at March 31, 2022 22.1% YoY revenue growth in Q1 to $59.1M 25.7% growth in metreleptin revenues YoY to $37.6M in Q1 9th consecutive quarter of positive EBITDA generation Successful bioavailability study supporting development of Mycapssa® for carcinoid symptoms in NET Conference call and webcast today at 0830 ET / 1330 BST DUBLIN, Ireland, and Boston MA, May 4, 2022, Amryt (NASDAQ:AMYT), a global, c

      5/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals

    $CHMA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Chiasma, Inc. (Amendment)

      SC 13G/A - CHIASMA, INC (0001339469) (Subject)

      8/9/21 4:06:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/24/21 4:29:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G filed by Chiasma, Inc.

      SC 13G - CHIASMA, INC (0001339469) (Subject)

      6/7/21 4:29:23 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    SEC Filings

    See more
    • SEC Form EFFECT filed by Chiasma, Inc.

      EFFECT - CHIASMA, INC (0001339469) (Filer)

      8/12/21 12:15:07 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Chiasma, Inc.

      15-12B - CHIASMA, INC (0001339469) (Filer)

      8/11/21 4:31:58 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form S-8 POS filed by Chiasma, Inc.

      S-8 POS - CHIASMA, INC (0001339469) (Filer)

      8/6/21 3:17:41 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Chiasma downgraded by Jefferies

      Jefferies downgraded Chiasma from Buy to Hold

      5/6/21 8:05:49 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • HC Wainwright resumed coverage on Chiasma with a new price target

      HC Wainwright resumed coverage of Chiasma with a rating of Buy and set a new price target of $12.00 from $10.00 previously

      3/2/21 7:26:29 AM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: STONEPINE CAPITAL, L.P. returned 6,770,000 units of Common Stock to the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/9/21 5:01:36 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: LUDLAM WILLIAM returned 11,799 units of Common Stock to the company, closing all direct ownership in the company

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:05:08 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Mamluk Roni

      4 - CHIASMA, INC (0001339469) (Issuer)

      8/5/21 6:00:07 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care

    $CHMA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CHMA
    Leadership Updates

    Live Leadership Updates

    See more
    • Amryt Reports Q3 2022 Financial and Operational Results

      Amryt Reports Q3 2022 Financial and Operational Results 8.2% YoY revenue growth in Q3 to $61.1M - 12.5% on a constant currency basis 11th consecutive quarter of positive EBITDA generation; $12.5M in Q3 2022 Operating cash flows of $14.3M for Q3 2022 Cash of $83.4M at September 30, 2022 Mycapssa® revenues increased 26.9% QoQ to $5.7M and 292.8% YoY CHMP positive opinion for Mycapssa® for the treatment of acromegaly in the EU Pathway agreed with the FDA to initiate a Phase 3 study for NET - expected in Q1 2023 Filsuvez® European launch progressing well Significant metreleptin LATAM $8.3M tender won - revenue expected to be recognized in Q4 Reaffirming FY 2022 revenue guidance to $26

      11/3/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Amryt Reports Record Q2 2022 Results

      Amryt Reports Record Q2 2022 Results 9.2% YoY revenue growth in Q2 to $68.5M 35.3% YoY revenue growth in Q2 excluding impact of a sporadic LATAM order in Q2 2021 7.8% growth in metreleptin revenues YoY to $46.4M in Q2 49.9% growth in metreleptin revenues in Q2 excluding impact of a sporadic LATAM order in Q2 2021 10th consecutive quarter of positive EBITDA generation Cash of $90.7M at June 30, 2022 Filsuvez® approved in the EU for the treatment of dystrophic and junctional EB Amryt now has four growing commercial products treating rare diseases Reaffirming FY 2022 revenue guidance to $260M - $270M, representing 17-21% YoY growth Stock repurchase program underway

      8/4/22 7:00:00 AM ET
      $AMYT
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

      Novel Vaccine Company Expands Leadership Team and Establishes US Presence SpyBiotech, a British biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, has appointed Mark Leuchtenberger as its Chief Executive Officer (CEO). He also joins the Board of Directors. Sumi Biswas, the company's co-founder, remains President and a Director and becomes Chief Scientific Officer (CSO). With the addition of Leuchtenberger, SpyBiotech establishes its presence in the United States with an office in Cambridge, Massachusetts. Mark Leuchtenberger recently served as Executive Chairman for Aleta Biotherapeutics and previously as CEO o

      7/12/22 5:00:00 AM ET
      $CHMA
      $NRSN
      Major Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pulmatrix appoints Director Anand Varadan

      LEXINGTON, Mass., July 27, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today announced the appointment of Anand Varadan to its Board of Directors, effective July 26, 2021. Mr. Varadan brings expertise in commercialization and successful product launches. In addition, Mark Iwicki stepped down from his role on the Board of Directors effective July 23, 2021. "We are delighted to welcome Anand to

      7/27/21 10:00:00 AM ET
      $PULM
      $CHMA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

      Phased launch of MYCAPSSA® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to reduce the burden of chronic injections for people with rare diseases, as evidenced by its recent initiation of a phased U.S. commercial launch of MYCAPSSA® as the first oral therapy for treatment of acromegaly, today announced financial results for the fourth quar

      3/4/21 4:01:00 PM ET
      $CHMA
      Major Pharmaceuticals
      Health Care